Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny blood test could unlock IVF pregnancy dangers

NCT ID NCT07477340

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at a hormone called relaxin in women who get pregnant through IVF. Researchers want to see if relaxin levels differ between fresh and frozen embryo transfers, and if low levels are linked to pregnancy complications. 60 first-time mothers will give an extra blood sample early in pregnancy. The goal is to learn why frozen embryo transfers may carry higher risks of conditions like preeclampsia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Relaxin measurement (blood test)
What this could lead to
If successful, this could help explain why some IVF pregnancies have higher risks of complications like preeclampsia, and may guide safer embryo transfer methods.
What could go wrong
This is a small, early observational study (60 people) that only measures a hormone level. It won't directly change treatment or prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will focus on patients who underwent fresh or frozen embryo transfer in the Reproductive Medicine Department and were monitored at the Women's and Children's Hospital, resulting in a progressive pregnancy with first trimester ultrasound.

Ages

18 to 45 years

Sex

Female participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Primiparous women * Intra-couple ART * Of childbearing age undergoing assisted reproductive technology (18 to 44 years and 11 months) * Who underwent a fresh or frozen embryo transfer during the inclusion period resulting in a progressing monofetal pregnancy (ultrasound showing an embryo with cardiac activity). * Able to understand the ins and outs of the study * Having indicated their willingness to participate in the study Exclusion Criteria: * Uterine pathologies (adenomyosis, fibroids) * Multiple pregnancies * Spontaneous pregnancy * Pregnancy through gamete donation * Refusal to undergo obstetric ultrasounds * Subject participating in interventional research involving an exclusion period still ongoing at the time of pre-inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Embryos transfert are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Embryos transfert Infertility

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de Médecine et de la Reproduction HFME

    Bron, Rhone, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.